ArticleBMC cancer2018
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.Clinical and experimental medicine · 2024Pooled it
- Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial.Blood advances · 2020Trial
- A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.Cancer medicine · 2026Article
- Renal Outcomes Following Autologous Stem Cell Transplantation in Dialysis-Dependent Patients With Multiple Myeloma: A Single-Center Study From a Low- and Middle-Income Country.Case reports in hematology · 2026Article
- Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.Blood cancer journal · 2024Observational
- Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery.BMC nephrology · 2024Article
- Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanter's nightmare!Blood cell therapy · 2024Article
- Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Article
- [How I treat multiple myeloma with renal impairment].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.Leukemia & lymphoma · 2020Article
- Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma.Cancer medicine · 2020Article
- Article
- Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.Clinical hematology international · 2019Article
- Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?Stem cells international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true.
methodsFrom a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR < 60 ml/min/1.73m
conclusionWhile severe RI at MM diagnosis confers a risk of shorter OS, MM progression after ASCT is not affected by any stage of renal failure. It can be concluded that ASCT can be safely carried out in MM patients with mild to moderate RI and should be pro-actively considered in those with severe RI.
resultsWhen comparing all groups, no difference in OS and PFS was found (p = 0.319 and p = 0.904). After further stratification according to the degree of RI at the time of diagnosis, an OS disadvantage was detected for patients with an eGFR < 45 ml/min/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.